| 1 | Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney | 1.9 | 1 | Citations (PDF) |
| 2 | Lipid-Lowering Treatment Gaps in Patients after Acute Myocardial Infarction: Using Global Database TriNetX | 2.2 | 3 | Citations (PDF) |
| 3 | 2022: The Year in Cardiovascular Disease – The Year of Upfront Lipid Lowering Combination Therapy. | 1.2 | 11 | Citations (PDF) |
| 4 | Effectiveness and feasibility of cardiovascular disease personalized prevention on high polygenic risk score subjects: a randomized controlled pilot study | 2.8 | 18 | Citations (PDF) |
| 5 | The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP) | 5.6 | 119 | Citations (PDF) |
| 6 | 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease | 2.2 | 1,453 | Citations (PDF) |
| 7 | Evaluation of a new semi-automated Hydragel 11 von Willebrand factor multimers assay kit for routine use | 1.9 | 7 | Citations (PDF) |
| 8 | Disclosing Pharmacogenetic Feedback of Caffeine via eHealth Channels, Assessment of the Methods and Effects to Behavior Change: A Pilot Study | 3.5 | 0 | Citations (PDF) |
| 9 | Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment | 9.6 | 29 | Citations (PDF) |
| 10 | Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP) | 6.0 | 53 | Citations (PDF) |
| 11 | Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) | 14.8 | 241 | Citations (PDF) |
| 12 | 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk | 2.2 | 7,333 | Citations (PDF) |
| 13 | European Society of Cardiology: Cardiovascular Disease Statistics 2019 | 2.2 | 885 | Citations (PDF) |
| 14 | Update of the position paper on arterial hypertension and erectile dysfunction | 0.6 | 43 | Citations (PDF) |
| 15 | Hypertension and Reproduction | 5.1 | 29 | Citations (PDF) |
| 16 | Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP) | 9.1 | 23 | Citations (PDF) |
| 17 | Macrovascular Complications of Type 2 Diabetes Mellitus | 1.4 | 307 | Citations (PDF) |
| 18 | Assessment of Associations Between Arterial Mechanical Properties and Biochemical Blood Markers for Early Detection of Atherosclerosis | 0.0 | 1 | Citations (PDF) |
| 19 | Aortic Augmentation Index is Dependent on Bodyside in Healthy Young Subjects | 2.7 | 0 | Citations (PDF) |
| 20 | Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial | 13.2 | 265 | Citations (PDF) |
| 21 | PATIENTS WITH ACUTE CORONARY SYNDROME, ELEVATED ATHEROGENIC LIPOPROTEINS, AND PRIOR CORONARY ARTERY BYPASS GRAFTING DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: INSIGHTS FROM THE ODYSSEY OUTCOMES TRIAL | 1.2 | 0 | Citations (PDF) |
| 22 | The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion | 0.8 | 38 | Citations (PDF) |
| 23 | 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk | 0.9 | 2,151 | Citations (PDF) |
| 24 | Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery | 1.2 | 61 | Citations (PDF) |
| 25 | Psychosocial Factors and Personality Traits and the Prevalence of Arterial Hypertension Among 35- and 55-Year-Old Men and Women in Sweden and Estonia: a SWESTONIA Longitudinal Study | 2.7 | 3 | Citations (PDF) |
| 26 | New Horizons in the Pathogenesis, Pathophysiology and Treatment of Familial Hypercholesterolaemia | 2.3 | 7 | Citations (PDF) |
| 27 | Construction of gender-specific regression models for aortic length estimation based on computed tomography images | 3.6 | 2 | Citations (PDF) |
| 28 | The Mechanisms of Actions of Aldosterone and its Antagonists in Cardiovascular Disease | 2.3 | 8 | Citations (PDF) |
| 29 | Preclinical evaluation of a semi‐automated and rapid commercial electrophoresis assay for von Willebrand factor multimers | 2.8 | 27 | Citations (PDF) |
| 30 | Stroke volume assessment by impedance cardiography: Comparative analysis with transthoracic echocardiography | 0.0 | 0 | Citations (PDF) |
| 31 | Pulse wave velocity and its gender-related associations with cardiovascular risk factors in a high cardiovascular risk population | 1.4 | 8 | Citations (PDF) |
| 32 | Second derivative photoplethysmographic signal analysis of differences between fingers in healthy subjects 2018, , 1-4 | | 1 | Citations (PDF) |
| 33 | Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) | 0.9 | 203 | Citations (PDF) |
| 34 | Rapid socio-economic changes, psychosocial factors and prevalence of hypertension among men and women aged 55 years at baseline in Estonia: a 13-year follow-up study | 1.9 | 1 | Citations (PDF) |
| 35 | 2018 ESC/ESH Guidelines for the management of arterial hypertension | 2.2 | 8,510 | Citations (PDF) |
| 36 | Non-invasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients: effects on home blood pressure in the BEAUTY study | 1.9 | 5 | Citations (PDF) |
| 37 | The Metabolic Profile of Stable Ischemic Heart Disease by Serum 1H NMR | 0.9 | 1 | Citations (PDF) |
| 38 | Investigation of photoplethysmographic signal augmentation index estimation differences between fingers | 0.0 | 2 | Citations (PDF) |
| 39 | Prevalence of cardiovascular disease risk factors in Tallinn, Estonia | 2.2 | 7 | Citations (PDF) |
| 40 | Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT | 0.6 | 28 | Citations (PDF) |
| 41 | Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia | 0.3 | 80 | Citations (PDF) |
| 42 | Aldehyde inhibition of antioxidant enzymes in the blood of diabetic patients | 3.1 | 30 | Citations (PDF) |
| 43 | Lipoprotein‐Associated Phospholipase A
<sub>2</sub>
Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease | 4.3 | 48 | Citations (PDF) |
| 44 | Tooth loss is independently associated with poor outcomes in stable coronary heart disease | 2.1 | 52 | Citations (PDF) |
| 45 | A randomized and controlled study of noninvasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients | 0.6 | 24 | Citations (PDF) |
| 46 | Pulse wave registration from radial artery using photoplethysmographic method 2015, 85, 6425-6428 | | 0 | Citations (PDF) |
| 47 | TOOTH LOSS IS INDEPENDENTLY ASSOCIATED WITH ADVERSE OUTCOME BUT NOT MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC CORONARY HEART DISEASE | 1.2 | 0 | Citations (PDF) |
| 48 | A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapy | 0.8 | 73 | Citations (PDF) |
| 49 | Modulation of Genetic Associations with Serum Urate Levels by Body-Mass-Index in Humans | 2.5 | 71 | Citations (PDF) |
| 50 | The Aortic Pulse Wave Velocity Estimation for Arterial Stiffness Assessment | 0.0 | 2 | Citations (PDF) |
| 51 | Management of erectile dysfunction in hypertension: Tips and tricks | 2.3 | 50 | Citations (PDF) |
| 52 | Photoplethysmographic signal waveform index for detection of increased arterial stiffness | 3.0 | 54 | Citations (PDF) |
| 53 | Impact of smoking: All-cause and cardiovascular mortality in a cohort of 55-year-old Swedes and Estonians | 2.4 | 7 | Citations (PDF) |
| 54 | 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension | 1.9 | 596 | Citations (PDF) |
| 55 | Prevalence and determinants of hypertension in Estonian adults | 2.4 | 11 | Citations (PDF) |
| 56 | Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes | 1.2 | 13 | Citations (PDF) |
| 57 | Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease | 25.1 | 524 | Citations (PDF) |
| 58 | Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): Results of the Dyslipidemia International Study (DYSIS) | 2.2 | 9 | Citations (PDF) |
| 59 | The initiation of free radical peroxidation of low-density lipoproteins by glucose and its metabolite methylglyoxal: a common molecular mechanism of vascular wall injure in atherosclerosis and diabetes | 3.2 | 56 | Citations (PDF) |
| 60 | Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient | 0.6 | 65 | Citations (PDF) |
| 61 | Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013) | 1.1 | 10 | Citations (PDF) |
| 62 | Identification of the hemodynamic modulators and hemodynamic status in uncontrolled hypertensive patients | 1.9 | 7 | Citations (PDF) |
| 63 | Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013) | 1.2 | 26 | Citations (PDF) |
| 64 | 2013 ESH/ESC Guidelines for the management of arterial hypertension | 1.9 | 367 | Citations (PDF) |
| 65 | 2013 ESH/ESC Guidelines for the management of arterial hypertension | 0.6 | 4,324 | Citations (PDF) |
| 66 | 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) | 0.6 | 834 | Citations (PDF) |
| 67 | The effect of local cold and warm exposure on index finger photoplethysmographic signal waveform 2013, 19, 2300-2303 | | 3 | Citations (PDF) |
| 68 | New Photoplethysmographic Signal Analysis Algorithm for Arterial Stiffness Estimation | 2.9 | 63 | Citations (PDF) |
| 69 | Lipid‐Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in High‐Risk Patients with and without Type 2 Diabetes Mellitus Inadequately Controlled Despite Prior Statin Monotherapy | 3.0 | 16 | Citations (PDF) |
| 70 | European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) | 2.2 | 5,444 | Citations (PDF) |
| 71 | Genome-wide association analyses identify 18 new loci associated with serum urate concentrations | 26.1 | 771 | Citations (PDF) |
| 72 | Sexual Function in Untreated and Treated Hypertension 2012, , 389-398 | | 0 | Citations (PDF) |
| 73 | Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk | 34.3 | 1,976 | Citations (PDF) |
| 74 | ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) | 2.2 | 2,894 | Citations (PDF) |
| 75 | Hypertension and sexual dysfunction: time to act | 0.6 | 67 | Citations (PDF) |
| 76 | Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study | 2.2 | 72 | Citations (PDF) |
| 77 | Blood Pressure Loci Identified with a Gene-Centric Array | 6.5 | 165 | Citations (PDF) |
| 78 | Cholesterol-rich low density lipoproteins are also more oxidized | 3.2 | 17 | Citations (PDF) |
| 79 | Efficacy of Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients With or Without Obesity | 1.3 | 3 | Citations (PDF) |
| 80 | HYPEST study: profile of hypertensive patients in Estonia | 2.1 | 9 | Citations (PDF) |
| 81 | Novel polymorphic AluYb8 insertion in the WNK1 gene is associated with blood pressure variation in Europeans | 4.1 | 24 | Citations (PDF) |
| 82 | Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease | 1.8 | 3 | Citations (PDF) |
| 83 | Cardiovascular disease risk factors in homeless people | 3.2 | 9 | Citations (PDF) |
| 84 | Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study | 3.1 | 168 | Citations (PDF) |
| 85 | Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome | 2.8 | 13 | Citations (PDF) |
| 86 | Setting-up a Blood Pressure and Vascular Protection Clinic: Requirements of the European Society of Hypertension | 0.6 | 11 | Citations (PDF) |
| 87 | Agreement within Europe about antihypertensive treatment and education – results from the European Society of Hypertension questionnaire | 0.6 | 2 | Citations (PDF) |
| 88 | Interrelation between Malonyl Dialdehyde-Dependent Modification and Cholesterol Content in Low-Density Lipoproteins | 0.7 | 1 | Citations (PDF) |
| 89 | Hypervariable intronic region in NCX1 is enriched in short insertion-deletion polymorphisms and showed association with cardiovascular traits | 2.0 | 9 | Citations (PDF) |
| 90 | Efficacy of Switching from Statin Monotherapy to Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients Analyzed by Baseline LDL-C | 2.0 | 0 | Citations (PDF) |
| 91 | Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High Risk Hypercholesterolemic Patients Stratified by Previous Statin Treatment Potency | 2.0 | 0 | Citations (PDF) |
| 92 | Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency | 3.8 | 6 | Citations (PDF) |
| 93 | Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis | 1.9 | 42 | Citations (PDF) |
| 94 | An experimental measurement complex for probable estimation of arterial stiffness 2010, , 194-197 | | 9 | Citations (PDF) |
| 95 | Polymorphisms in the WNK1 Gene Are Associated with Blood Pressure Variation and Urinary Potassium Excretion | 2.5 | 45 | Citations (PDF) |
| 96 | Targeting 160 Candidate Genes for Blood Pressure Regulation with a Genome-Wide Genotyping Array | 2.5 | 103 | Citations (PDF) |
| 97 | Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document | 0.6 | 1,492 | Citations (PDF) |
| 98 | Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations | 3.1 | 174 | Citations (PDF) |
| 99 | Experiences of Telemedicine-Aided Hypertension Control in the Follow-Up of Finnish Hypertensive Patients | 2.6 | 7 | Citations (PDF) |
| 100 | Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document | 1.9 | 356 | Citations (PDF) |
| 101 | N-acetyltransferase 8, a positional candidate for blood pressure and renal regulation: resequencing, association and in silico study | 2.0 | 25 | Citations (PDF) |
| 102 | SLC2A9 Is a High-Capacity Urate Transporter in Humans | 8.2 | 343 | Citations (PDF) |
| 103 | Assessment of Pulse Wave Velocity and Augmentation Index in different arteries in patients with severe coronary heart disease | 0.0 | 9 | Citations (PDF) |
| 104 | 2007 Guidelines for the Management of Arterial Hypertension | 0.6 | 4,880 | Citations (PDF) |
| 105 | ESH Hypertension Excellence Centres: a new strategy to combat an old foe | 0.6 | 1 | Citations (PDF) |
| 106 | Risk factor control in treated hypertensives from Estonia and Sweden. Why the difference? | 1.9 | 5 | Citations (PDF) |
| 107 | Resequencing PNMTin European hypertensive and normotensive individuals: no common susceptibilily variants for hypertension and purifying selection on intron 1 | 2.0 | 12 | Citations (PDF) |
| 108 | A psychosocial comparison of 35- and 55-year-old men and women in sweden and estonia: The swestonia cardiovascular risk factor study | 1.4 | 3 | Citations (PDF) |
| 109 | Title is missing! | 2.2 | 0 | Citations (PDF) |
| 110 | The Renin-Angiotensin System in Essential Hypertension: Associations with Cardiovascular Risk | 1.9 | 24 | Citations (PDF) |
| 111 | The Baltic Atherosclerosis Journal | 2.7 | 1 | Citations (PDF) |
| 112 | Effect of ciprofibrate on platelet aggregation in patients with combined hyperlipidemia | 2.4 | 1 | Citations (PDF) |
| 113 | Platelet Aggregation, Thromboxane A<sub>2</sub>, Prostacyclin Generation and Platelet Sensitivity to Prostacyclin during the First Month after Myocardial Infarction | 2.4 | 2 | Citations (PDF) |
| 114 | Antiaggregative Therapy with Acetylsalicylic Acid and Diclofenac in Patients with Acute Myocardial Infarction | 3.2 | 1 | Citations (PDF) |
| 115 | Antithrombotic effect and reperfusion by low molecular weight heparin in a canine model of coronary artery thrombosis. | 1.0 | 4 | Citations (PDF) |
